Justin Byers watched too many drug programs fail not because of bad science, but because critical data was trapped in silos nobody could connect. He's now building Axio BioPharma to solve that problem and a pre-seed fund to back Midwest biotech founders who can't get a first meeting on the coasts.
No transcript available.